Incidental venous thromboembolism in cancer patients
It is well known that patients with cancer are at high risk of venous thromboembolism (VTE), especially when initiating...
Most Read
Unveiling the Link: Neutrophil Extracellular Traps, Occult Cancer, and VTE
Neutrophils, the predominant white blood cells in humans, hold a vital function within the immune response by serving...
Patient Empowerment: Educating Cancer Patients about Thrombosis Risk
Cancer patients have a higher risk of developing venous thromboembolism (VTE) when compared with non-cancer patients....
CAT treatment in challenging patient categories: what the literature says
Patients with cancer are at high risk of venous thromboembolism (VTE). Fortunately, patient survival, diagnostic tools...
Disseminated Intravascular coagulation in solid and hematological cancers
Introduction There is a clear relationship between malignancy and deranged coagulation. Patients with cancer are at...
Bleeding complications and platelet dysfunction in patients with lymphoproliferative disease receiving Bruton tyrosine kinase inhibitors
Ibrutinib (IBR) is an irreversible inhibitor of Bruton tyrosine kinase (Btk) that is approved for the treatment of...
Management of the incidents of VTE in cancer patients
During the ICTHIC webinar, “Updates in cancer-associated thrombosis,” Dr. Luis Jara-Palomares gave a lecture on the...
COVID-19 Hemostasis and Malignancy: the Bergamo Experience
The COVID-19 pandemic took one of its biggest tolls on Italy, and especially in the northern area, in Lombardy. In this...
Developmental hemostasis and its relevance to pediatric thrombosis
The coagulation system of neonates and children evolves with age, as evidenced by marked physiological differences in...
Rapping about new anticoagulants for CAT at ICTHIC 2018
Rapping about new anticoagulants for CAT at ICTHIC 2018 Cancer patients are four or five times as likely to develop...